Neurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX - Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued a hold rating and a $138.00 price target on the stock.

A number of other research analysts have also commented on the stock. HC Wainwright decreased their price target on shares of Neurocrine Biosciences from $190.00 to $185.00 and set a "buy" rating on the stock in a research note on Friday. Piper Sandler reaffirmed an "overweight" rating and issued a $160.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Bank of America dropped their price target on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday. Royal Bank of Canada decreased their price objective on Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a report on Friday. Finally, UBS Group lifted their target price on Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $166.90.

Neurocrine Biosciences Trading Down 1.6 %

Shares of NBIX traded down $1.96 during mid-day trading on Tuesday, reaching $116.85. The company's stock had a trading volume of 2,804,651 shares, compared to its average volume of 1,321,272. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The business has a 50-day simple moving average of $138.66 and a two-hundred day simple moving average of $131.23. The stock has a market cap of $11.83 billion, a P/E ratio of 35.52 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.45%. Research analysts anticipate that Neurocrine Biosciences will post 6.53 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jude Onyia sold 2,331 shares of the company's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total transaction of $294,381.99. Following the completion of the transaction, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 1,091 shares of the firm's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $338,445. This trade represents a 30.32 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 222,693 shares of company stock valued at $32,718,279. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Caprock Group LLC bought a new position in shares of Neurocrine Biosciences during the fourth quarter valued at $236,000. Plato Investment Management Ltd lifted its holdings in Neurocrine Biosciences by 2,481.9% during the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company's stock worth $1,263,000 after buying an additional 10,548 shares during the period. Swiss National Bank grew its position in shares of Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company's stock valued at $34,416,000 after buying an additional 4,100 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at about $3,236,000. Finally, KBC Group NV boosted its holdings in Neurocrine Biosciences by 78.3% in the third quarter. KBC Group NV now owns 18,972 shares of the company's stock valued at $2,186,000 after acquiring an additional 8,332 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.